阿尔茨海默病背后的生理病理机制:一个叙事审查
Eliasz Engelhardt1, Elisa de Paula França Resende2,3, Karina Braga Gomes4
1Universidade Federal do Rio de Janeiro, Instituto de Neurologia Deolindo Couto, Rio de Janeiro RJ, Brazil.
Dementia & neuropsychologia
|December 19, 2024
概括
本综述汇编了阿尔茨海默病 (AD) 假设,重点关注粉样质斑块和神经纤维细胞. 识别关键分子可能使得早期的AD诊断和患者选择疗法成为可能.
科学领域:
- 神经病理学神经病理学
- 神经退行性疾病 神经退行性疾病
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样斑块和神经纤维状,导致神经元损失.
- 粉样蛋白级联假说表明,功能障碍的粉样蛋白代谢启动了AD病理,包括tau蛋白异常.
- 这些病理特征对于理解AD进展和开发诊断工具至关重要.
研究的目的:
- 编制有关阿尔茨海默病 (AD) 病理生理学的现有假设.
- 突出涉及AD发展的生物学途径.
- 为了确定早期AD诊断的潜在生物标记物和治疗干预的患者分层.
主要方法:
- 对当前科学文献进行叙述性审查.
- 编制和分析关于AD病变发生的假设.
- 确定关键的分子通路和潜在的生物标志物.
主要成果:
- 该综述综合了有关阿尔茨海默病 (AD) 神经病理学的主要假设.
- 讨论了关键的分子参与者和促进粉样斑块和神经纤维状结形成的途径.
- 突出了早期AD检测和患者选择的潜在生物标志物.
结论:
- 了解AD病理生理学对于开发有效的诊断和治疗策略至关重要.
- 识别参与AD途径的特定分子可以促进早期诊断.
- 生物标志物的发现对于在临床试验和治疗中有针对性的患者选择至关重要.
关键词:
阿尔茨海默病 阿尔茨海默病粉样蛋白是什么 粉样蛋白是什么粉样蛋白质斑块 (amyloid plaque) 是一种粉样蛋白质斑块 (amyloid plaque) 的组成部分.生物标志物 生物标志物神经纤维状团的神经纤维状团蛋白质是一种蛋白质.更多相关视频
相关概念视频
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
Parkinson's Disease: Overview
476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
442
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
442
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K


